Merck KGaA said the FDA approved a joint tumor drug it licensed from Abbisko, bringing a new option for rare noncancerous tumors that impact joints. The approval expands the clinical label for a therapy pathway that had been developed in parallel in a China-based portfolio before licensing to Merck KGaA. The move matters for rare-disease oncology and translational partnerships because it highlights how regulatory outcomes for uncommon indications can shift the value of early external innovation. It also reinforces Merck KGaA’s strategy of bringing late-stage assets into its portfolio via licensing arrangements. While the release did not add full prescribing details in the provided text, the approval timing sets up next steps that typically include uptake planning, evidence generation plans for broader populations, and possible lifecycle work depending on safety and response durability in real-world use.